(vianews) - the market ended the session with medincell (medcl.pa) jumping 11.56% to €7.14 on friday while cac 40 jumped 0.75% to €7,315.07.
medincell's last close was €6.40, 39.05% below its 52-week high of €10.50.
about medincell
medincell s.a. develops various therapeutic solutions in france. it develops solutions based on bepo, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. the company's products in development include mdc-irm, a risperidone extended-release injectable suspension completed phase iii trial for use in the treatment of schizophrenia; mdc-cwm, a sustained-release formulation of celecoxib in phase iii trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-tjk, a subcutaneous injection in phase iii trials for use in the treatment of schizophrenia. its product candidates in preclinical trials, such as mdc-ang, an antipsychotic product for use in the treatment of schizophrenia; mdc-ttg for covid-19 and its variants; mdc-grt for use in organ transplant; mdc-wwm for contraception; mdc-stm for use in malaria; mdc-kpt for use in acute pain for pets; and mdc-irm for use in neuroscience. the company was incorporated in 2003 and is based in jacou, france.
earnings per share
as for profitability, medincell has a trailing twelve months eps of €-1.06.
volatility
medincell's last week, last month's, and last quarter's current intraday variation average was 0.40%, 0.12%, and 2.22%.
medincell's highest amplitude of average volatility was 0.95% (last week), 1.22% (last month), and 2.22% (last quarter).
yearly top and bottom value
medincell's stock is valued at €7.14 at 22:31 est, way below its 52-week high of €10.50 and way above its 52-week low of €4.73.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, medincell's stock is considered to be oversold (<=20).
revenue growth
year-on-year quarterly revenue growth grew by 77140%, now sitting on 9.89m for the twelve trailing months.
more news about medincell (medcl.pa).